Growth Hormone Physiology and Disorders

Growth hormone, clinically known as somatotropin, is a master regulator that orchestrates linear growth during childhood and maintains metabolic homeostasis throughout life. A firm grasp of its physiology is not only foundational for endocrinology but is also frequently tested on exams like the MCAT, as disorders of its secretion have profound and visible clinical consequences.

Pulsatile Secretion and Hypothalamic Control

Growth hormone (GH) is secreted by somatotroph cells in the anterior pituitary gland, but its release is not constant. It occurs in a pulsatile fashion, with major surges during deep sleep and after exercise. This pattern is crucial for its biological activity and is tightly regulated by two key hypothalamic hormones. Growth hormone-releasing hormone (GHRH) stimulates both the synthesis and release of GH. In contrast, somatostatin (also known as growth hormone-inhibiting hormone) tonically inhibits GH secretion. The balance between these signals determines the pulsatile output. For the MCAT, it's vital to remember that this hypothalamic-pituitary axis is a classic example of endocrine regulation, where the hypothalamus releases factors that control the pituitary, which in turn secretes hormones targeting end organs.

Mechanism of Action: IGF-1 Signaling and Metabolic Effects

GH exerts its effects both directly and indirectly. Its primary role in promoting linear growth is mediated indirectly through insulin-like growth factor 1 (IGF-1). When GH binds to receptors on hepatocytes (liver cells), it stimulates the production and release of IGF-1. IGF-1 then acts on epiphyseal growth plates in long bones, stimulating chondrocyte proliferation and bone elongation. This GH-IGF-1 axis is the central driver of postnatal growth. Beyond growth, GH has direct metabolic actions. It is diabetogenic, meaning it raises blood glucose levels by promoting gluconeogenesis in the liver and inducing insulin resistance in peripheral tissues. Concurrently, it stimulates lipolysis, breaking down fat stores, and promotes protein anabolism in muscle. Think of GH as a hormone that mobilizes energy reserves (fat) for growth while ensuring glucose is available for the brain, even if it makes the body slightly more insulin resistant.

Disorders of Excess: Gigantism and Acromegaly

Excess GH, most commonly from a benign pituitary adenoma, leads to distinct clinical syndromes depending on when it occurs relative to epiphyseal plate closure. In children and adolescents, before growth plates fuse, excess GH causes gigantism. This is characterized by proportional, accelerated linear growth resulting in very tall stature. Consider a patient vignette: a 10-year-old boy presents with rapid height increase far above his growth curve, along with coarse facial features and large hands and feet. In adults, after plate closure, the same excess leads to acromegaly. Here, growth occurs in acral (extremity) and soft tissues. Adults present with enlarging hands and feet, coarse facial features (prominent brow, nose, and lips), macroglossia (enlarged tongue), and conditions like carpal tunnel syndrome. Systemic complications include hypertension, cardiomyopathy, glucose intolerance, and an increased risk of colonic polyps. For exam purposes, the key discriminator is timing: gigantism in open growth plates, acromegaly in closed.

Disorders of Deficiency: Short Stature and Beyond

Growth hormone deficiency in children leads to short stature. The growth failure is often proportional, and children may appear younger than their chronological age. Causes can be congenital (e.g., genetic mutations, structural brain defects) or acquired (e.g., pituitary tumors, trauma, radiation). It's crucial to distinguish GH deficiency from other causes of short stature, such as hypothyroidism or genetic syndromes. In adults, GH deficiency, though less common, can lead to decreased muscle mass, increased visceral adiposity, dyslipidemia, reduced bone density, and diminished quality of life. Diagnosis hinges on stimulation tests, as random GH levels are unreliable due to pulsatile secretion. On the MCAT, you might encounter questions linking pediatric short stature to the failure of the GH-IGF-1 axis, emphasizing the importance of systematic hormonal assessment.

Clinical Assessment and Therapeutic Strategies

Diagnosing GH disorders integrates clinical evaluation with dynamic testing. For suspected acromegaly, the initial screening test is the measurement of IGF-1 level, which integrates GH pulses and is thus stable throughout the day. This is followed by an oral glucose tolerance test; in healthy individuals, glucose suppresses GH, but in acromegaly, GH levels fail to suppress. For deficiency, provocative tests using agents like insulin-induced hypoglycemia or arginine are used to assess the pituitary's ability to secrete GH. Treatment strategies are targeted. GH-secreting tumors are first addressed with surgical resection, often followed by medical therapy with somatostatin analogs (which mimic the inhibitory hormone) or GH receptor antagonists. Radiation is a third-line option. For GH deficiency, the treatment is recombinant human GH replacement therapy, which is highly effective in promoting growth in children and improving body composition in adults.

Common Pitfalls

1. Confusing Gigantism and Acromegaly Based on Symptoms Alone: A common mistake is to associate tall stature only with gigantism and coarse features only with acromegaly. Remember, both disorders can present with coarse features. The critical differentiator is the patient's age and growth plate status. In an exam scenario, always note if the patient is a child or an adult.
2. Misinterpreting Random GH Levels: Because GH secretion is pulsatile, a single random measurement is nearly useless for diagnosing deficiency or excess. Relying on it is a classic error. Instead, understand that IGF-1 is the screening marker for excess, and stimulation tests are required for deficiency.
3. Overlooking the Direct Metabolic Actions of GH: It's easy to focus solely on IGF-1-mediated growth. Don't forget that GH itself directly influences carbohydrate and lipid metabolism. In a patient with acromegaly, the onset of diabetes mellitus is a direct consequence of GH's anti-insulin effects, not just a coincidental finding.
4. Assuming All Short Stature is Due to GH Deficiency: While GH deficiency is a cause, it is not the most common. Failing to consider other etiologies like constitutional delay of growth, malnutrition, or chronic disease before jumping to GH testing reflects a narrow diagnostic approach.

Summary

• Growth hormone (somatotropin) is secreted in pulsatile bursts from the anterior pituitary, primarily stimulated by GHRH and inhibited by somatostatin from the hypothalamus.
• GH promotes linear growth indirectly by stimulating the liver to produce IGF-1, which acts on bone growth plates. It also has direct diabetogenic and lipolytic metabolic effects.
• GH excess before epiphyseal closure causes gigantism (proportional tall stature), while after closure it causes acromegaly (acral and soft tissue overgrowth).
• GH deficiency in children results in short stature and requires stimulation tests for diagnosis, as random GH levels are unreliable.
• Clinical management involves precise diagnostic tests like IGF-1 measurement and glucose suppression tests for excess, and hormone replacement or surgical intervention based on the specific disorder.